RECENT COMMENTS

Constantinos Zambirinis (Thyroid cancer management): As you mentioned above, differentiated thyroid cancer is followed after treatment with the thyroglob [...]   »Read more

Dr Lobna Sedky (Serigne Magueye Gueye): Within Africa,the scope of cancer differs even between various geographic regions. Being an oncologi [...]   »Read more

DR PUSHKAL DWIVEDI (World Cancer Declaration): I FULLY AGREE!   »Read more

Dr Olayinka O Adegbehingbe (World Cancer Declaration): Dear Prof Franco Cavalli, The World Cancer Declaration is great and impacts in developing countries [...]   »Read more

Tung Dinh Nguyen (World Cancer Declaration): Dear Dr F Cavalli, I have had a lot of chance to see Dr F. Cacalli In Hue, Vietnam. The World Ca [...]   »Read more

Spotlight on

Issue 33
Should we expect better from the media? A conversation with health journalists
Addicted to wonder drugs
Mass media's hit or myth approach to cancer
Issue 29
Europa Donna launches Breast Health Day
Issue 27
Bringing truths about cancer to new audiences: The UICC’s Reel Lives film festival showcases 33 of the best
Issue 25
Tackling cancer in the Middle East: Euro-Arab School of Oncology contributes a mix of international and local expertise
Issue 24
European leukaemia Network: making fragmentation a thing of the past
Issue 22
ECCO seeks heeling touch for oncology's lost voice
Issue 21
New breastcare network seeks to push up standards across the globe
Issue 20
ESO marks 25 years of championing excellence in cancer education
Issue 19
AACR marks 100 years of researching cancer
Issue 18
MRI directive threatens the care of Europe's cancer patients
Issue 17
What they never taught you at medical school
Issue 16
Not (just) another declaration
Closing the survival gap
Issue 15
Record-breaking stamp raises sticky questions
Helping the media to get the message
Issue 14
Quality cancer care 
ASCO and ESMO consensus statement
Issue12
Chernobyl 20 years on - the cancer incidence graphs are still rising
Putting cancer on the global agenda
Issue 10
Can science win back public trust?
FECS opens its doors to organ-based oncologists
Coming out for breast cancer, country by country
Issue 9
Radiotherapy report sets new targets for Europe
Issue 8
ESMO Minimum Clinical Recommendations
MEPs join forces against cancer
Issue 6
Rising to the challenge in the developing world  
Does your hospital pass the palliative care test?
Issue 5
Women doctors offer alternative to costly mammography 
Poorer countries take their place at the World Cancer Conference  
Issue 4
TITAN - Nurses to get frontline training in haematological toxicities
ESO: undergraduate courses - Inspiring the oncologists of tomorrow   
Issue 3
Flims: Building the next generation of clinical researchers  
Issue 2
EIO: A truly European Centre to rival the best 
Issue 1
EBCC: Driving up standards in breast care 

 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

GR109 - The challenge of ovarian cancer in relapse

GR110 - Permanent implant prostate brachytherapy: The state-of-the-art

GR111 - Breast cancer chemoprevention: What is new?

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, GlaxoSmithKline, Merck and Novartis.